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ABSTRACT 
3 H-Androst-5-ene-17-one-3B-pl sulfate is converted 
to 3B-androst-5-ene-lW-ol-3f3-yl sulfate by soluble ex- 
tracts of rat testis in the presence of added NAM%2 or 
NADPH2. The conversion was approximately 4 times greater 
than the conversion of 3H-androst-5-ene-17-one-3B_ol to 
3%androst-5-ene+3@,17&diol under similar incubation 
conditions. The same extracts converted 3H-androst- 
5-ene-17-one-3@-ol to 3H-androst-5-ene-17-one-3+yl 
sulfate in the presence of added ATP and Yg++., 
INTRODUCTION 
In an earlier report from this laboratory2, iL was 
demonstrated that soluble enzyme preparations from several 
endocrine tissues, i.e., rat testis and bovine adrenal 
cortex, ovary, and corpus luteum, sulfurylate estradiol- 
1?$3. Recent in vivo 3*4*5 and in vitro a,7 studies __I_ _I- 
demonstrating that steroid sulfates can serve as metabolic 
intermediates led us to investigate whether the above- 
mentioned preparations also catafyze metabolic inter- 
conversions of steroid sulfates. In the present 
investigation it was demonstrated that these prepara- 
tions sulfurylate dehydroepiandrosterone and that they 
convert dehydroepiandrosterone sulfate to androst-5- 
enediol-3-sulfate, Possible relations of these 
observations to the in vivo conversion of dehydroepi- -- 
androsterone and its sulfate to testosterone are discussed. 
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EXPERIMENTAL 
Materials 
7a-3H-Dehydroepiandrosterone (DBA) (1.15 c/mM) and 
the ammonium salt of 7u-3H-Dehydroepiandrosterone sulfate 
(DHA-S) (1.7 c/mM) were purchased from New England 
Nuclear Corporation. DHA-S was purified by paper chroma- 
tography in 0.4 M NaHC032. The purity of DHA was 
checked by paper chromatography in hexane-benzene/form- 
amide. Androst-5-ene-3B,17S-diol, dehydroepiandro- 
sterone, NADH2 and NADPH2 were obtained from Sigma 
Chemical Company. 
Preparation of carrier sulfates 
DHA was sulfurylated by a modification of the 
method described by Morren8. Pyridine (4.2 ml) was 
added dropwise with shaking to 1.5 ml of chlorosul- 
fonic acid in 60 ml of CC14. Three grams of DHA 
dissolved in a minimum amount of chloroform was 
added dropwise to the reaction mixture, The mixture 
was allowed to stand for 30 minutes in the cold, and 
then was heated on a steam bath for 30 minutes. After 
cooling the solid material was collected and stirred 
with a mixture of 25 ml of water and 13.5 ml of con- 
centrated ammonium hydroxide. Pyridine was removed by 
ether extraction and residual ether was removed by 
evaporation. Boiling water (65 ml) was added. The 
solution was heated to dissolve solid material and 
was then filtered and allowed to cool. The crystals were 
collected and dried. They were recrystallized from 
water. 
The ammonium salt of androstenediol-3-sulfate was 
prepared by reducing DHA-S. Two g of the ammonium salt 
of DHA-S was dissolved in 50 ml methyl alcohol and the 
solution was cooled in ice. Sodium borohydride (200 mg) 
was added. The solution was then warmed to room tempera- 
ture and allowed to stand overnight. Acetone (8 ml) 
was added to decompose the excess sodium borohydride. 
After addition of 2.4 ml of water the solution was 
placed in the freezer. The sodium metaborate which 
separated was filtered off, and the solution was evapo- 
rated to dryness. The residue was recrystallized from 
a mixture of methyl alcohol and ether. 
The ammonium salt of androstenediol-3-sulfate-17- 
acetate was prepared from the ammonium salt of androstene- 
diol-3-sulfate by dissolving the latter in pyridine- 
acetic anhydride, 2:l (v/v), and allowing the solution 
to stand overnight at room temperature. The excess 
reagent was removed under vacuum with slight warming and 
the residue recrystallized from a mixture of methanol 
and ether. 
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Melting points and infrared spectra of the DHA-S 
and androstenedio1-S preparations agreed well with 
those previously published5. Each compound migrated 
as a single component on paper chromatography in system 
SL-1 and, after solvolysis, in systems Z-l, Z-2 and Z-3 
(see Results). 
Incubation and extraction 
Testes were obtained from Holtzman rats. Soluble 
extracts of the tissue were prepared, lyophylized, and 
stored at -loo as described earlierg. 
Seven pc 3H-DHA-S (0.0226 pmoles) or 6.25 JX 3H-DHA 
(0.0171 pmoles) was incubated in a rotary agitator for 
2 hrs at 37O in one ml of 0.2 M potassium phosphate 
buffer (pH 7.4) containing lyophylized testis extract 
equivalent to 10.5 mg of protein and 10 mg of NADH2 
or NADPH2. The DHA was first dissolved in 0.03 ml 
of absolute ethanol before addition to the buffer 
solution. After incubation, the steroid sulfates and 
free steroids were extracted as described previously2. 
Detection of steroids and measurement of radioactivity 
Radioactive compounds on chromatograms were local- 
ized with a Vanguard Autoscanner 880; authentic steroid 
sulfates were detected by the technique of Crepy and 
JudaslO, free steroids with phosphomolybdic acid rea- 
gentll. Radioactivity was measured in a Packard Tri- 
Carb scintillation spectrometer. The scintillation 
solution consisted of 0.3% 2,5-diphenyloxazole (PPO) 
and 0.01% 1,4-bis-2-(5-phenyloxazolyl)-benzene (POPOP) 
in toluene (w/v). 
Relative amounts of the radioactive products on 
chromatograms were determined by cutting out the 
specific area, submerging it in scintillation solution, 
and counting. 
The specific activities of 3H-DHA-S and of 3H-andro- 
stenediol-3-sulfate-17-acetate was determined by 
dissolving weighed amounts of the crystals in a known 
volume of methanol and counting duplicate 0.2 ml ali- 
quots in 7 ml of scintillation solution. Radioactivity 
is reported without correction for quenching. 
RESULTS 
Identification--a. Steroid sulfates--The aqueous 
extracts from the DHA-S incubations containing the 
steroid sulfates were chromatographed in duplicate 
in the Schneider-Lewbart system No. 1 (SL-1)12, 
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along with authentic steroid sulfates. Only one radio- 
active area was observed. Since this system did not 
separate DBA-S from androstenediol-3-sulfate, the 
radioactive area from one chromatogram was eluted with 
methanol, divided into two samples, and evaporated to 
dryness. To one of the samples, 40 pg of authentic 
androstenediol-3-sulfate was added. Both samples were 
then subjected to acetylation (see Experimental). The 
resulting products were dissolved in methanol and re- 
chromatographed in SL-1. Two radioactive areas were 
observed, one with the mobility of DBA-S, the other 
with the mobility of androstenediol-3-sulfate-17- 
acetate. After localizing the radioactive areas, the 
chromatogram derived from the sample to which carrier 
androstenediol-3-sulfate had been added before acetyla- 
tion was treated with the Crepy reagent to determine 
that all of the added carrier had been acetylated and 
that the radioactive product migrated with authentic 
androstenediol-3-sulfate-17-acetate. 
The other chromatogram was used to determine the 
relative amounts of the two compounds detected after 
acetylation. Following counting, in scintillation 
fluid the radioactive compound which migrated with the 
authentic androstenediol-3-sulfate-17-acetate was re- 
covered from the paper by elution with methanol and evap- 
oration to dryness. The residue was dissolved in water 
and filtered to remove material derived from the scin- 
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TABLE 1 
PROOF OF RADIOCREMICAL PURITY OF THE ACETATE DERIVATIVE 
n 
OF ENZYMICALLY-FORMED ?I-ANDROSTENEDIOL-3-SULFATE 
Crystallization& Weight Specific Activity 
(mg.) (c.p.m./mg.) 
After Addition of 
Carrier Androstenediol- 
3-sulfate-17-acetate 30.1 11.2 x lo2 
First Crystallization 25.2 11.3 
Mother Liquor 4.6 11.4 
Second Crystallization 15.7 11.8 
Mother Liquor 7.7 12.1 
Third Crystallization 13.4 11.7 
Mother Liquor 1.4 11.6 
aCrystallization of a representative sample from methanol- 
ether 
tillation solution as described by Wallace and Silber- 
man13. Carrier androstenediol-3-sulfate-17-acetate 
(30.1 mg) was added to this aqueous solution and evapor- 
ated to dryness. The residue was recrystallized three 
times from methanol-ether without significantly altering 
the specific activity (Table 1). 
Additional evidence that the product formed from 
DRA-S was androstenediol-3-sulfate was obtained by sub- 
jecting the other SL-1 chromatogram to solvolysis for 
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12 
180 minutes . The solvolyzed products were eluted with 
methanol, the methanol evaporated, and the free steroids 
extracted three times from water into methylene chloride. 
The methylene chloride was evaporated and the products 
applied to paper along with authentic DHA and androsten- 
ediol for chromatography (Table 2) in two of the 
following systems: formamide as stationary phase and 
hexane-benzene, 1:l (v/v), as mobile phase (Z-l system); 
formamide as stationary phase and benzene as mobile phase 
(2-2 system)14; triethylene glycol as stationary phase 
15 and toluene as mobile phase (Z-3 system) . Two radio- 
active areas were observed, one migrating with DHA and 
the other with androstenediol. The two radioactive 
areas were cut out and counted to determine the rela- 
tive 
also 
amounts of the two 
The ether extracts 
chromatographed in 
steroid was detected at 
the Vanguard scanner 
16 
, 
compounds (Table 2). 
from the DHA-S incubations were 
the above systems. No free 
the most sensitive setting of 
indicating that no cleavage 
of DHA-S to the free steroid had occurred during the in- 
cubation and isolation procedures. 
b. Free steroids--The dried ether extracts containing 
the free steroids from the DHA incubation were chromato- 
graphed (Table 3) on methanol-washed Whatman No. 1 paper 
along with authentic steroids in two of the three systems 
as described for the solvolyzed steroid sulfates. In each 
of the three systems, only two radioactive areas were 
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aseven PC 3H-DHA-S (0.0226 @moles) was incubated in a rotary 
agitator for 2 hrs at 370 in one ml of 0.2 M potassium phos- 
phate buffer (pH 7.4) containing lyophylized testis extract 
equivalent to 10.5 mg of protein and the indicated amount of 
NATXi2 and NADPH2. 
b Per cent conversion t (counts/min of 3H-androstenediol- 
Q-sulfate) + <counts/min of 3H-DHA-S) + (couats/min of 
%I-androstenediol-3-sulfate) x 100. 
observed, one migrating with DHA and the other with 
androstenediol. These areas were cut out and counted 
in scintillation vials to obtain the relative amounts of 
the two compounds (Table 3). The aqueous extracts from 
the DHA incubations were chromatographed in the SL-1 
system and scanned for radioactivity. No steroid sulfates 
330 STEROIDS 6:3 
were detected at the most sensitive setting of the Van- 
16 
guard scanner . 
TABLE 3 
CONVJZRSION OF 3H-DHA TO 3H-ANDROSTENEDIOL 
DV A SOLUBLE EXTRACT OF RAT TESTES8 
Experiment Added Chromatography Per Cent 


















=Tritiated 3H-DHA (6.25 kc; 0.0171 pmoles) was incubated in a 
rotary agitator for 2 hrs at 37O in one ml of 0.2 M potassium 
phosphate buffer (pH 7 4) containing lyophylized testis 
extract equivalent to 10.5 mg of protein and the indicated 
amount of NADH2 and NADpH2. 
b 
Per cent conversi 
s 
n = (counts/min of 3H-an rostenediol 
f (counts/min of 9 H-androstene- 
;liol) x 100 
H-DHA) + (counts/min of 
Extent of conversion--Between 93.7% and 99.9% of the 
incubated radioactivity was recovered in the extracts. 
Since the substrate and one product were the only de- 
tectable radioactive compounds on chromatograms of 
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these extracts, it seemed appropriate to express the 
extent of conversion to the product as a per cent of 
the sum of the counts/min of extracted product plus 
counts/min of extracted substrate. Per cent conversion 
TABLE 4 
CRYSTALLIZATION OF ENZYMICALLY-FORMED 3H-DERYDROEPIANDRO- 
STERONE-SULFATE TO CONSTANT SPECIFIC ACTIVITY 
Crystallization' Weight Specific Activity 
(mg.1 (c.p.m./mg.) 
After Addition of 
Carrier Dehydroepiandro- 
sterone-Sulfate 18.7 6.0 x lo2 
First Crystallization 13.8 5.6 
Mother Liquor 4.3 8.6 
Second Crystallization 8.5 4.6 
Mother Liquor 4.1 5.3 
Third Crystallization 4.8 4.7 
Mother Liquor 3.0 4.5 
'Crystallized from methanol-ether 
of DHA-S to androstenediol-3-sulfate and of DHA to 
androstenediol are presented in Tables 2 and 3 respective- 
ly. The data demonstrate that the conversion of DBA-S 
to androstenediol-3-sulfate was approximately four times 
greater than the conversion of DHA to androstenediol. 
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A somewhat greater degree of conversion was obtained with 
NADPH2 than with NADH2 with both substrates. 
Sulfurvlation of DHA--To determine whether the testi- 
cular extracts could sulfurylate DHA, 12.5 WC DHA 
(0.0342 pmoles) was incubated in phosphate buffer con- 
taining testicular extract equivalent to 10.5 mg protein 
plus ATP and Mg++ as described earlier for estradiol- 
17p2. The aqueous extract obtained by the extraction 
procedure2 was chromatographed in the SL-1 system. A 
radioactive area migrating with reference DHA-S was 
observed. This product was eluted, added to carrier 
DHA-S and recrystallized to constant specific activity 
(Table 4). The amount of DHA sulfurylated represented 
less than 1% of the incubated DHA. Total recovery of 
the radioactivity added as DHA in two incubation mix- 
tures was 99.9% and 96.6%. 
DISCUSSION 
Direct interconversion of DHA-S and androstenediol- 
3-sulfate has been observed in vivo. Baulieu et al. 
3 
-- -- 
demonstrated the direct conversion of androstenediol- 
3-sulfate to DHA-S in humans and reported preliminary 
observations suggesting that the reverse reaction 
takes place. Roberts et al. 5 also presented evidence -- 
for the direct reduction in humans. The present study 
demonstrates this conversion in a soluble enzyme prep- 
aration from rat testis. 
That the interconversion as reported in this study 
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occurred by direct reduction, rather than by inter- 
mediate hydrolysis, reduction, and sulfurylation is 
supported by the observations that: a) the extent of 
conversion of DHA-S to androstenediol-3-sulfate in 2 
hours was 4 times as great as the conversion of DHA to 
androstenediol, b) no radioactive free steroid was de- 
tected after incubation of DHA-S, and c) no radioactive 
conjugated steroid was detected after incubation of DHA 
in the absence of added ATP and Mg++. An indirect inter- 
conversion would not be expected from observations in - 
vitro with other tissues showing that: a) sulfatase 
activity is largely restricted to the microsome fraction 17 
and, when present, is strongly inhibited by inorganic 
phosphate 
18,19 
, and b) sulfurylation requires added 
ATP and Mg ++20,21 . 
The present study identifies rat testis as one 
tissue possessing enzymes capable of catalyzing the 
reduction of DHA-S to androstenediol-3-sulfate. It 
is probable that this activity is shared by other 
tissues that have 17-dehydrogenase activity. It occurs 
in tissues other than testis since it has been demon- 
strated in vivo in human females 335 . The reaction has -- 
also been reported to occur in rabbit liver slices 22 . 
We have found in preliminary studies that soluble 
extracts of bovine ovary also catalyze the reduction 
but were less active than the rat testis extracts. 
Present speculation concerning the role of the 
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reduction of DHA to androstenediol in steroid meta- 
bolism is concerned with the possibility that this may 
be the first reaction in the conversion of DHA to 
testosterone. The utilization of DHA in the biosynthesis 
of testosterone has been established in vivo 
23,24 
and in _- - 
vitro2!j. Recent reports by several authors 
24,26,27,28 
provide evidence thata major pathway exists for the 
synthesis of testosterone from DHA that does not involve 
androstenedione as an obligatory intermediate, and these 
authors suggest androstenediol may be the intermediate. 
Thds suggestion is supported by reports of the conversion 
of androstenediol to testosterone by bacterial prepara- 
29 
tions , by rat testicular suspensions 30 , and by homo- 




Also, Klempien et al. , -- using isolated dog liver, 
identified androstenediol as a major intermediate in 
the conversion of DRA to testosterone. In a more 
recent study, Rosner et a1.25 reported the isolation -- 
of androstenediol from rabbit testis homogenates that 
had been incubated with DHA and the conversion of the 
enzymatically-synthesized androstenediol to testosterone 
by the same homogenates. 
The conversion of DRA-S into testosterone has been 
demonstrated by Aakvag et al. 
33 
in perfused canine testis -- 
and ovary. However, the reaction sequence in this con- 
version was not demonstrated. They were unable to 
detect any free DHA in the spermatic vein after infusion 
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of DHA-S into the spermatic artery, suggesting that DHA-S 
may be reduced to androstenediol-3-sulfate prior to the 
cleavage of the sulfate ester to the free steroid. The 
finding in the present study that DHA-S was converted 
to androstenediol-3-sulfate by rat testis extracts and 
that this conversion was much more efficient than the 
conversion of DHA to androstenediol provides support 
for this suggestion. 
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